Shenzhen Key Laboratory of ENT, Institute of ENT & Longgang ENT Hospital, Shenzhen 518172, China.
Shenzhen Key Laboratory of ENT, Institute of ENT & Longgang ENT Hospital, Shenzhen 518172, China.
J Ethnopharmacol. 2019 Mar 1;231:275-282. doi: 10.1016/j.jep.2018.11.038. Epub 2018 Nov 26.
ETHNOPHARMACOLOGICAL RELEVANCE: Yan-Hou-Qing (YHQ), a Chinese medicine formula containing fourteen kinds of materials, has been designed for pharyngitis and cough treatment in Oriental medicine. In the present study, the anti-allergic effects and underlying mechanisms of YHQ in inhibition of airway hyper responsiveness (AHR) was explored in an ovalbumin (OVA)-induced allergic asthma mouse model. MATERIALS AND METHODS: BALB/c mice were sensitized by OVA and cholera toxin (CT) and challenged with OVA intranasally to induce allergic asthma mouse model. YHQ (200 mg/kg) was orally administered for 3 weeks from week-2 after OVA sensitization. The AHR and histological changes of lung tissues were evaluated by whole-body barometric plethysmography analysis and hematoxylin and eosin (H&E) staining, respectively. The serum concentration of OVA-specific IgE and T helper 2 (Th2) cytokines (IL-4 and IL-13) were determined by enzyme-linked immune sorbent assay (ELISA). Flow cytometry was performed to evaluate the percentage of CD4CD25Foxp3 regulatory T cells (Treg) in the spleen. RESULTS: The elevated AHR responses, heavier inflammatory cell infiltration and Th2 cytokines in allergic asthma group indicated Ovalbumin-induced asthmatic mouse models were built successfully. Compared to allergic asthma group, OVA-induced AHR responses and eosinophil infiltration in lung were improved significantly, and the productions of OVA-specific IgE and Th2 cytokines, IL-4 and IL-13, in the serum were also reduced dramatically after the treatment of YHQ. Moreover, YHQ treatment significantly increased the percentage of CD4CD25Foxp3 Treg in OVA-induced allergic asthma mouse model. CONCLUSIONS: YHQ improves the allergic asthma related symptoms via promotion of CD4CD25Foxp3 Treg and suppression of Th2 responses in mouse model, suggesting YHQ can be used as a potent agent to alleviate allergic asthma related symptoms.
民族药理学相关性:咽炎清(YHQ)是一种包含 14 种成分的中药配方,被设计用于东方医学中的咽炎和咳嗽治疗。在本研究中,我们探讨了 YHQ 在卵清蛋白(OVA)诱导的过敏性哮喘小鼠模型中抑制气道高反应性(AHR)的抗过敏作用及其潜在机制。
材料和方法:BALB/c 小鼠通过 OVA 和霍乱毒素(CT)致敏,并通过鼻内给予 OVA 来诱导过敏性哮喘小鼠模型。从 OVA 致敏后第 2 周开始,YHQ(200mg/kg)通过口服给药 3 周。通过全身压力体积描记法分析和苏木精和伊红(H&E)染色分别评估 AHR 和肺组织的组织学变化。通过酶联免疫吸附试验(ELISA)测定血清 OVA 特异性 IgE 和辅助性 T 细胞 2(Th2)细胞因子(IL-4 和 IL-13)的浓度。通过流式细胞术评估脾中 CD4CD25Foxp3 调节性 T 细胞(Treg)的百分比。
结果:与过敏性哮喘组相比,OVA 诱导的 AHR 反应和嗜酸性粒细胞浸润在肺中得到了显著改善,血清中 OVA 特异性 IgE 和 Th2 细胞因子 IL-4 和 IL-13 的产生也显著降低。此外,YHQ 治疗还显著增加了 OVA 诱导的过敏性哮喘小鼠模型中 CD4CD25Foxp3 Treg 的百分比。
结论:YHQ 通过促进 CD4CD25Foxp3 Treg 和抑制 Th2 反应来改善过敏性哮喘相关症状,提示 YHQ 可作为一种有效的药物来缓解过敏性哮喘相关症状。
Naunyn Schmiedebergs Arch Pharmacol. 2024-5
Front Immunol. 2021-5-20
BMC Complement Med Ther. 2020-9-14
Immunopharmacol Immunotoxicol. 2019-5-7